Therapeutic drug monitoring in the treatment of tuberculosis.
about
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisUse of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerationsRecommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsPharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in TanzaniaThe Role of Adherence and Retreatment in De Novo Emergence of MDR-TBQuantifying Isoniazid Levels in Small Hair Samples: A Novel Method for Assessing Adherence during the Treatment of Latent and Active TuberculosisPredictors of Prolonged TB Treatment in a Dutch Outpatient SettingNew anti-tuberculosis drugs and regimens: 2015 updateInsights into the pharmacokinetic properties of antitubercular drugs.Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA.Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014Advances in the diagnosis and treatment of tuberculosis.Plasma drug activity in patients on treatment for multidrug-resistant tuberculosisUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania.Plasma drug activity assay for treatment optimization in tuberculosis patients.Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA.Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis.Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetesHealth system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.Tuberculosis and diabetes mellitus: convergence of two epidemics.Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patientsInteraction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteersIsoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infectionDrug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.Pharmacokinetics of ethionamide in children.Therapeutic drug monitoring in the treatment of active tuberculosisPharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Therapeutic drug monitoring of antimicrobials.
P2860
Q26775974-7A4FFFE3-74B7-4A86-983A-B9DF37ED9167Q28072205-D8A38369-95CF-4374-9680-8B83B8E81B4FQ28079207-1BDD475A-4C3A-41D5-BC96-FF8F804F0E7FQ28550488-E6110C59-2482-435D-9640-9FA5C10FEDDFQ28550707-1B3D6487-5F27-4EA4-9810-38206055F532Q28552186-5FC68695-7DF0-40F1-8465-E03E90BFBA15Q28553471-84DEBDFC-9544-4422-9737-6502A3EBD6BCQ28596775-A246604B-E630-4A24-B233-031A16CE8F75Q30251497-55915141-98A8-4438-BFC9-C8D99724928CQ30274831-6A17D905-511E-4B3B-B4A8-C1F0E25EF31FQ30300207-4088ED37-64C6-4B31-9ED1-EB25D83FA67AQ30353049-59646AEA-6CC8-4EF0-AA94-2808F61B9AFDQ30411475-8623536F-AC44-4C1C-A950-E6BD2CBE49CCQ30411703-58944767-4D9A-423E-BA39-046BE3052538Q30415746-C3D5DD4E-9208-46E9-9A1D-8A12528E7E31Q30415943-849DEAB6-4A9A-4807-B8CC-B86AA88617C4Q30426583-AB842077-9AB4-4D51-B05D-A6DFEF500C02Q30427912-BAD3E026-926C-4D3F-9BB7-00007EAFE05BQ33282527-CF356CB7-99AD-4CB1-9B0D-5C77A3A2C5D6Q33291134-EE1D4657-6679-494F-9CE7-7B1188AC633EQ33521011-93A5944C-6BA9-4CE9-A280-C63E972D4C04Q33576421-9B2CD46B-1EAC-443A-BD2D-7EEAC42B915CQ33797850-37D51E20-3359-4661-A7B1-6D94C226D456Q34156234-586D25E9-DDDD-43BA-B3A2-6DB74E409304Q34298935-D440D8D1-D886-4913-81F5-9873E395C279Q34561741-1B209BE6-D938-4063-A226-8E556D657E8CQ34597564-6FD95D51-E701-4C67-B119-DDF9F767FC60Q34600493-BECAC10B-F504-488D-A700-6BFDAF65E995Q34729493-B290ACCD-6FA9-48AB-AE40-8EABFE6C16E2Q34922554-97D7158C-6DE2-43CE-B5A3-C75DC4C10EFCQ34981779-0E4D81C3-C4F2-4090-91ED-FA3449D6D87EQ35028452-BE0CA5ED-EB41-4CB2-A356-A654E960A272Q35120591-FCAC6C86-D6F5-48FD-A110-BBF276A0C2BDQ35167178-7D842240-DE20-4943-BF13-F3475D1943C4Q35215680-06FB2B2F-EB1C-4F10-AC39-4B42FF89C2EDQ35270526-3B396917-F833-4544-BA4E-DE5BB9B4E8DDQ35487794-EFD14668-2BCD-430A-8827-FBBF4CF0A708Q35598492-FF04D5A2-72DA-4906-90EB-2CA72C29F1CAQ35617587-29CDA3F3-9C94-43F7-B6A1-8C6F4C823842Q35640430-E5DB2108-4785-4B62-8646-0EB76022CA15
P2860
Therapeutic drug monitoring in the treatment of tuberculosis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Therapeutic drug monitoring in the treatment of tuberculosis.
@ast
Therapeutic drug monitoring in the treatment of tuberculosis.
@en
Therapeutic drug monitoring in the treatment of tuberculosis.
@nl
type
label
Therapeutic drug monitoring in the treatment of tuberculosis.
@ast
Therapeutic drug monitoring in the treatment of tuberculosis.
@en
Therapeutic drug monitoring in the treatment of tuberculosis.
@nl
prefLabel
Therapeutic drug monitoring in the treatment of tuberculosis.
@ast
Therapeutic drug monitoring in the treatment of tuberculosis.
@en
Therapeutic drug monitoring in the treatment of tuberculosis.
@nl
P1433
P1476
Therapeutic drug monitoring in the treatment of tuberculosis.
@en
P2093
Charles A Peloquin
P304
P356
10.2165/00003495-200262150-00001
P577
2002-01-01T00:00:00Z
P5875
P6179
1019504416